Monday, March 27, 2017 9:24:53 AM
1. Start of last remaining Ph2 trial. For sure in Q2, likely in April or May.
2. Novartis signing the option. The "trigger" to sign is the start of the last remaining Ph2 trial. "Trigger" is a direct quote from Conatus CEO Mentos.
Then there are many catalysts later in 2017 and throughout 2018. 2017 will have some big milestone payments. 2018 will have even bigger milestone payments based on the trial results as they are announced.
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM